Inozyme (INZY) Pharma announced the publication of a paper titled, “Phenotypic characterization of ENPP1 deficiency: generalized arterial calcification of infancy and autosomal recessive hypophosphatemic rickets type 2” in JBMR Plus that characterizes the severity and progression of ENPP1 Deficiency. Inozyme collaborated with leading disease experts Carlos Ferreira, M.D., of the National Institutes of Health, Frank Rutsch, M.D., of Munster University Children’s Hospital and other global contributors to collect natural history data in the largest retrospective analysis of ENPP1 Deficiency published to date.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INZY:
- Buy Rating on Inozyme Pharma: Promising Potential of INZ-701 and Market Opportunity
- Inozyme price target lowered to $12 from $24 at Raymond James
- Inozyme price target lowered to $23 from $30 at Piper Sandler
- Inozyme Pharma Focuses on ENPP1 Deficiency Program
- Inozyme reports prioritization of ENPP1 Deficiency program, workforce reduction